Bristol Myers Squibb (CELG-RI) Other Accumulated Expenses (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 16 years of Other Accumulated Expenses data on file, last reported at $12.6 billion in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $12.6 billion, down 23.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.6 billion (down 23.6% YoY), and the FY2025 annual result was $17.6 billion, down 3.01% from the prior year.
• Other Accumulated Expenses fell to $12.6 billion in Q1 2026 per CELG-RI's latest filing, from $17.6 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $19.3 billion in Q3 2025 and troughed at $12.4 billion in Q1 2022.
• A 5-year average of $15.5 billion and a median of $15.9 billion in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses gained 22.48% in 2024, then declined 23.6% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $14.6 billion in 2022, then gained by 8.9% to $15.9 billion in 2023, then rose by 14.11% to $18.1 billion in 2024, then fell by 3.01% to $17.6 billion in 2025, then dropped by 28.24% to $12.6 billion in 2026.
• Business Quant data shows CELG-RI's Other Accumulated Expenses at $12.6 billion in Q1 2026, $17.6 billion in Q4 2025, and $19.3 billion in Q3 2025.